Risk Indicators in Patients With Ventricular Fibrillation During Acute Myocardial Infarction

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2005 by Heidelberg University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Heidelberg University
ClinicalTrials.gov Identifier:
NCT00175942
First received: September 10, 2005
Last updated: NA
Last verified: May 2005
History: No changes posted
  Purpose

Sudden cardiac death is in most cases triggered by ischemia-related ventricular tachyarrhythmias and accounts for 50% of deaths from cardiovascular disease in developed countries. Chronic elevation of indicators of coagulation activation has been found in patients with coronary heart disease , but a role of coagulation activation and proinflammatory state as a potential risk factor for ventricular fibrillation (VF) during acute myocardial infarction has not been investigated.


Condition
Acute Myocardial Infarction
Sudden Cardiac Death

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Indicators of Coagulation Activation and Inflammation Contributing to Ventricular Fibrillation Complicating Acute Myocardial Infarction

Resource links provided by NLM:


Further study details as provided by Heidelberg University:

Estimated Enrollment: 300
Study Start Date: February 2003
Detailed Description:

Sudden cardiac death (SCD) is in most cases triggered by ischemia-related ventricular arrhythmias and is responsible for 50% of the mortality from cardiovascular disease in developed countries (1). Chronic elevation of indicators of coagulation activation and inflammation has been found in patients with coronary heart disease and may contribute to vasculatory disorders probably contributing to the development of arrhythmogenesis. However, the role of coagulation activation as a potential risk factor for ventricular fibrillation during acute myocardial infarction has not been investigated yet.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

ST-elevation myocardial infarction ventricular fibrillation during acute MI

Exclusion Criteria:

NSTEMI coagulation disorders, e.g.intake of coumadin

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00175942

Contacts
Contact: Elif Elmas, MD, Dr. 00496213833988
Contact: Martina Brückmann, MD, Dr.

Locations
Germany
University Hospital of Mannheim, University of Heidelberg Recruiting
Mannheim, Germany, 68167
Sub-Investigator: Elif Elmas, MD. Dr         
Sponsors and Collaborators
Heidelberg University
Investigators
Principal Investigator: Carl E. Dempfle, Prof.Dr. University Hospital of Mannheim, University of Heidelberg
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00175942     History of Changes
Other Study ID Numbers: 0229.3
Study First Received: September 10, 2005
Last Updated: September 10, 2005
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Heidelberg University:
acute myocardial infarction
ventricular fibrillation
coagulation
inflammation

Additional relevant MeSH terms:
Death, Sudden, Cardiac
Infarction
Myocardial Infarction
Ventricular Fibrillation
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Heart Arrest
Death, Sudden
Death
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on September 16, 2014